Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IMG-1
- Development stage
- Preclinical
- Lead developer
- Imagine Pharma
- Modality
- Peptides
01
Overview
IMG-1 is a novel polypeptide discovered by Imagine Pharma. It represents a first-in-kind therapeutic approach, with significant scientific achievements reported by the company. As of October 2023, the drug and its associated programs are in development, but detailed information about its mechanism of action, specific indications, or clinical trial status has not been publicly disclosed. The available data suggest that IMG-1 is being developed as an innovative treatment platform; however, no specifics regarding disease targets or modality (e.g., small molecule, peptide drug) have been released[2].
- Other names
- Lung Healing (IMG-1 program)
02
Targets
Ribosomal protein (Ribosomal protein family)
Beyond the preview
Go deeper on IMG-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IMG-1.